PaxMedica, Inc. Common Stock
PXMD
PXMD was delisted on the 1st of May, 2024.
6 hedge funds and large institutions have $96.1K invested in PaxMedica, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$59.8K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$49.8K |
| 3 |
VF
Virtu Financial
New York
|
+$46.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$20.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.21K |
Top Sellers
PXMD Hedge Fund Activity: Q3 2022 in Review
6 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in PaxMedica, Inc. Common Stock (PXMD) for Q3 2022, worth a combined $96.1K.
Buyers outnumbered sellers: 6 funds opened new PXMD positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $59.8K.
- 6 institutional investors held PaxMedica, Inc. Common Stock (PXMD) as of Q3 2022, up from 0 in Q2 2022.
- Funds reported $96.1K of PaxMedica, Inc. Common Stock stock for Q3 2022.
- 6 funds opened new PaxMedica, Inc. Common Stock positions in Q3 2022 and 0 closed out, a net change of +6 holders.
- The largest PaxMedica, Inc. Common Stock buyer in Q3 2022 was Jane Street, an estimated $59.8K added.
Based on aggregated 13F filings for Q3 2022.